When the school bus driver passed out on a four-lane highway due to an asthma attack, quick-thinking middle school students sprang into action. Sixth grader Jackson Casnave took control of the steering wheel, while Darrius Clark hit the brakes, successfully guiding the bus to the median and into park. Simultaneously, other students administered medication to the driver, called for help, and informed the transportation team. These heroic actions prevented a potential crash and ensured the safety of all 40 students on board.
Read More
The death of 22-year-old Cole Schmidtknecht highlights a critical flaw in the US healthcare system. His asthma medication, Advair Diskus, experienced a drastic price increase due to Pharmacy Benefit Managers (PBMs) manipulating formularies to maximize profits. This resulted in Cole lacking preventative medication, leading to a fatal asthma attack. His parents are now suing OptumRx and Walgreens, advocating for legislation requiring advanced notice of formulary changes and increased transparency within the PBM system. The Schmidtknechts’ tragedy underscores the urgent need for reform to prevent similar preventable deaths.
Read More
Research from King’s College London reveals benralizumab, an injectable drug already used for severe cases, as the first new asthma attack treatment in 50 years. Targeting eosinophils, a type of white blood cell contributing to lung inflammation, the therapy significantly reduced treatment failure rates compared to steroids (45% vs. 74%) in a 158-person trial. This new approach offers improved symptoms, quality of life, and reduced hospitalizations, potentially impacting the two million asthma attacks annually in the UK. While further large-scale trials are needed, the findings suggest a potential “game-changer” in asthma and COPD treatment.
Read More
John Q. Hosedrinker